JP2002517245A5 - - Google Patents

Download PDF

Info

Publication number
JP2002517245A5
JP2002517245A5 JP2000553585A JP2000553585A JP2002517245A5 JP 2002517245 A5 JP2002517245 A5 JP 2002517245A5 JP 2000553585 A JP2000553585 A JP 2000553585A JP 2000553585 A JP2000553585 A JP 2000553585A JP 2002517245 A5 JP2002517245 A5 JP 2002517245A5
Authority
JP
Japan
Prior art keywords
polypeptide
gpi
conjugate
antibody
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000553585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002517245A (ja
Filing date
Publication date
Priority claimed from US09/328,199 external-priority patent/US6858210B1/en
Application filed filed Critical
Publication of JP2002517245A publication Critical patent/JP2002517245A/ja
Publication of JP2002517245A5 publication Critical patent/JP2002517245A5/ja
Pending legal-status Critical Current

Links

JP2000553585A 1998-06-09 1999-06-09 治療的および診断的ドメイン1β2GPIポリペプチドおよびその使用の方法 Pending JP2002517245A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8865698P 1998-06-09 1998-06-09
US60/088,656 1998-06-09
US10308898P 1998-10-05 1998-10-05
US60/103,088 1998-10-05
US09/328,199 US6858210B1 (en) 1998-06-09 1999-06-08 Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US09/328,199 1999-06-08
PCT/US1999/013194 WO1999064595A1 (en) 1998-06-09 1999-06-09 THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME

Publications (2)

Publication Number Publication Date
JP2002517245A JP2002517245A (ja) 2002-06-18
JP2002517245A5 true JP2002517245A5 (cg-RX-API-DMAC7.html) 2006-08-03

Family

ID=27376031

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000553585A Pending JP2002517245A (ja) 1998-06-09 1999-06-09 治療的および診断的ドメイン1β2GPIポリペプチドおよびその使用の方法

Country Status (12)

Country Link
US (2) US6858210B1 (cg-RX-API-DMAC7.html)
EP (1) EP1092027B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002517245A (cg-RX-API-DMAC7.html)
KR (1) KR20010052713A (cg-RX-API-DMAC7.html)
CN (1) CN1310759A (cg-RX-API-DMAC7.html)
AT (1) ATE346922T1 (cg-RX-API-DMAC7.html)
AU (1) AU772851B2 (cg-RX-API-DMAC7.html)
CA (1) CA2329942A1 (cg-RX-API-DMAC7.html)
DE (1) DE69934228T2 (cg-RX-API-DMAC7.html)
ES (1) ES2275348T3 (cg-RX-API-DMAC7.html)
PT (1) PT1092027E (cg-RX-API-DMAC7.html)
WO (1) WO1999064595A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
CA2376057A1 (en) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
EP1210124A2 (en) * 1999-07-29 2002-06-05 Epix Medical, Inc. Targeting multimeric imaging agents through multilocus binding
CN1399562A (zh) 1999-11-28 2003-02-26 拉卓拉药物公司 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
CA2414076A1 (en) * 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
AU2002229639A1 (en) * 2000-12-13 2002-06-24 De Haard, Johannes Joseph Wilhelmus Camelidae antibody arrays
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
CA2492803C (en) * 2002-07-19 2013-11-05 The General Hospital Corporation Oxime conjugates and methods for their formation and use
AU2003303524A1 (en) * 2002-12-27 2004-07-29 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
DE10310082A1 (de) * 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-bindende Doxorubicin-Peptid-Derivate
WO2004089422A2 (en) * 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
CA2591914C (en) * 2005-01-24 2017-04-25 Board Of Regents, The University Of Texas System Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
JP4898785B2 (ja) * 2005-04-18 2012-03-21 バイオ−ラッド ラボラトリーズ,インコーポレイティド リン脂質及び補因子タンパク質の共有結合による固相固定化
WO2008036449A2 (en) * 2006-06-29 2008-03-27 The Regents Of The University Of California Chemical antibodies for immunotherapy and imaging
US20080015145A1 (en) * 2006-07-11 2008-01-17 Maria Gyongyossy-Issa Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions
JP5461581B2 (ja) * 2009-01-02 2014-04-02 フライサン ディベロップメント カンパニー リミテッド 自己免疫疾患を診断するための合成ペプチド、方法およびキット
WO2011163568A1 (en) * 2010-06-24 2011-12-29 University Of Kansas Conjugates comprising an n-oxime bond and associated methods
CN105273080A (zh) * 2014-07-14 2016-01-27 于珮 一种还原型β2-糖蛋白Ⅰ的制备方法
US10098960B2 (en) 2015-04-03 2018-10-16 Ucl Business Plc Polymer conjugate
TWI572617B (zh) * 2016-01-20 2017-03-01 國立陽明大學 重組β-醣蛋白胜肽及其於抗腫瘤之應用
CN105801694A (zh) * 2016-05-03 2016-07-27 上海科新生物技术股份有限公司 一种抗心磷脂/β2糖蛋白I复合物的嵌合抗体
WO2019028336A1 (en) * 2017-08-03 2019-02-07 The Cleveland Clinic Foundation IMPROVED PEPTIDE EXPRESSION AND ANTIBODY DETECTION OF APO-H SPECIFIC SUBJECT
WO2022195051A1 (en) * 2021-03-18 2022-09-22 Université De Genève Peptides and use thereof for diagnosing and treating antiphospholipid syndrome
CN115894270B (zh) * 2022-10-10 2024-09-06 深圳市迪克曼生物科技有限公司 一种神经酰胺及其制备方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191668A (en) 1977-02-03 1980-03-04 Scripps Clinic And Research Foundation Induction of immunological tolerance
US5126131A (en) 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US5370871A (en) 1983-01-24 1994-12-06 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
ATE134880T1 (de) 1988-04-04 1996-03-15 Lawrence A Potempa Bindung von immunkomplexen durch modifizierte formen von c-reaktiven proteinen
CA2044142A1 (en) 1989-10-19 1991-04-20 Eiji Matsuura Carrier for binding of anti-phospholipid antibodies, an immunoassay method using the same and a kit therefor
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5162515A (en) 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
CA2058769C (en) 1990-04-06 1999-03-02 Steven Anthony Krilis Methods for determining phospholipids and antibodies thereof
CA2098281A1 (en) 1990-12-17 1992-06-18 Howard M. Dintzis Suppression of immune responses of oligomeric forms of antigen of controlled chemistry
IE922292A1 (en) 1991-07-15 1993-01-27 Jolla Pharma Modified phosphorous intermediates for providing functional¹groups on the 5' end of oligonucleotides
EP0600088B1 (en) 1992-02-05 1998-12-30 Yamasa Corporation Solid-phase reagent and assay of antibody using the same
FR2701263B1 (fr) 1993-02-09 1995-04-21 Elie Stefas Procédé d'obtention d'une composition aqueuse protéinique, composition correspondante, glycoprotéine contenue et son utilisation pour la stabilisation de l'albumine et la détection ou le dosage d'anticorps.
EP1808183A3 (en) 1993-09-08 2009-07-01 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
WO1995014231A1 (en) 1993-11-16 1995-05-26 Yamasa Corporation Method of assaying antiphospholipid antibody and kit therefor
FR2722991B1 (fr) 1994-08-01 1996-10-11 Orstom Utilisation de la beta2-glycoproteine i sous au moins une de ses formes comme agent anti-infectueux et composition pharmaceutique corrrespondante
JPH08333390A (ja) 1995-04-07 1996-12-17 Hoechst Japan Ltd ペプチド及びそれからなる自己免疫疾患治療剤
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5780319A (en) 1996-04-19 1998-07-14 Pasteur Sanofi Diagnostics Immunoassays to detect antiphospholipid antibodies
EP0954531A1 (en) 1996-06-06 1999-11-10 Lajolla Pharmaceutical Company aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
DE19637770A1 (de) 1996-09-16 1998-03-19 Koenig & Bauer Albert Ag Verfahren und Anlage zum automatischen Zu- und Abführen von Rollen
ATE262539T1 (de) 1996-11-12 2004-04-15 Hope City Immunoreaktive peptid ctl epitope von menschlichem cytomegalovirus
GB9805477D0 (en) 1998-03-13 1998-05-13 Oxford Glycosciences Limited Methods and compositions for diagnosis of rheumatoid arthritis
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
IL125262A0 (en) 1998-07-07 1999-03-12 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
IL126447A (en) 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
CA2373016A1 (en) 1999-05-04 2000-11-09 Genethor Gmbh Method for diminishing specific immune reactions
CA2376057A1 (en) 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
AUPQ272699A0 (en) 1999-09-09 1999-09-30 Unisearch Limited Use of beta2GPI in diagnostic tests for autoimmune diseases
CN1399562A (zh) 1999-11-28 2003-02-26 拉卓拉药物公司 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
US20010051351A1 (en) 2000-03-27 2001-12-13 Racis Stanley Paul Antigen-specific immune complex-based enzyme-linked immunosorbent assay
US20020150898A1 (en) 2000-04-18 2002-10-17 Tang Y. Tom Novel nucleic acids and polypeptides
AU2001263006A1 (en) 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
DE10048417A1 (de) 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Verbindungen mit verzweigtem Linker

Similar Documents

Publication Publication Date Title
Skriner et al. Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease.
Freimuth et al. Coxsackievirus and adenovirus receptor amino-terminal immunoglobulin V-related domain binds adenovirus type 2 and fiber knob from adenovirus type 12
Czajkowsky et al. Submolecular resolution of single macromolecules with atomic force microscopy
POOLE et al. Studies of the membrane topology of the rat erythrocyte H+/lactate cotransporter (MCT1)
Woodgate et al. UmuC mutagenesis protein of Escherichia coli: purification and interaction with UmuD and UmuD'.
JP2003501038A5 (cg-RX-API-DMAC7.html)
US20120220534A1 (en) Biomarker for neurodegeneration in neurological disease
JPH06510192A (ja) 推定上のhcv e2/ns1蛋白に対するモノクローナル抗体およびその使用方法
Berg et al. Mitochondrial antigen/antibody systems in primary biliary cirrhosis: revisited
Jones et al. Immunodominant autoepitopes of type VII collagen are short, paired peptide sequences within the fibronectin type III homology region of the noncollagenous (NC1) domain
Ohnuma et al. Large hepatitis B surface antigen polypeptides of Dane particles with the receptor for polymerized human serum albumin
EP1985705A3 (en) Nucleotide sequences of pestivirus strains, polypeptides encoded by these sequences and use thereof for diagnosis and prevention of pestivirus infections
Miralles et al. Electron tomography reveals posttranscriptional binding of pre-mRNPs to specific fibers in the nucleoplasm
Palmer et al. Characterization of the autoantibody responses to recombinant E3 binding protein (protein X) of pyruvate dehydrogenase in primary biliary cirrhosis
CA1313818C (en) Nuclear antigen la
Das et al. Epitope mapping of antibodies to acetylcholine receptor. alpha. subunits using peptides synthesized on polypropylene pegs
Sasaki et al. Dimer model for the microfibrillar protein fibulin‐2 and identification of the connecting disulfide bridge
JPH09509052A (ja) 肝炎c型ウイルスエンベロープ遺伝子用の哺乳動物発現系
Chatterjee et al. Homology of adenoviral E3 glycoprotein with HLA-DR heavy chain.
Mygland et al. Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis
JP2008515388A5 (cg-RX-API-DMAC7.html)
Caswell et al. Location of ryanodine receptor binding site on skeletal muscle triadin
Park et al. Targeted destruction of the polymerized human serum albumin binding site within the preS2 region of the HBV surface antigen while retaining full immunogenicity for this epitope
Worobec et al. Location of the antigenic determinants of conjugative F-like pili
WO2003097814A3 (en) Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins